EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY-NC-ND 4.0

A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease

Jonathan Q Trinh iD, Subodh M Lele, Benjamin A Teply iD

The Prostate · 2023-06 · 83 (8) · 814-819

DOI: 10.1002/pros.24521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Prostate, online erschienen am 26.03.2023. Verfasst von Jonathan Q Trinh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Adenoids, Prostatic Neoplasms, Carcinoma, Adenoid Cystic, Basal Cell Carcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic adenoid cystic (basal cell) carcinoma of the prostate is an exceedingly rare disease entity. As a result, no current consensus exists for optimal systemic therapy.

Methods

We present a patient with metastatic adenoid cystic (basal cell) carcinoma of the prostate who subsequently received systemic treatment, including chemotherapy and immunotherapy. We comprehensively reviewed all published data on therapy outcomes in advanced disease.

Results

Our patient benefited from combination chemotherapy (carboplatin and paclitaxel), with objective radiographic response and reduction in cancer‐related pain. However, chemotherapy was stopped due to cumulative neurotoxicity, and subsequent immunotherapy with atezolizumab did not produce any response. Our literature review revealed inconsistent outcomes with various treatments but showed most promise with chemotherapy. Targeted therapy and immunotherapy seem to benefit specific cases, and androgen deprivation therapy had minimal evidence of benefit.

Conclusion

Based on the findings of our case report and literature review, we suggest platinum‐based chemotherapy doublets as first‐line treatment for metastatic cases of adenoid cystic (basal cell) carcinoma of the prostate, reserving targeted therapy or immunotherapy for select cases based upon molecular profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoidsProstatic NeoplasmsCarcinoma, Adenoid CysticBasal Cell CarcinomaSkin NeoplasmsMaleHumansProstateAndrogen AntagonistsRare Diseases

Stichwörter der Autor:innen

adenoid cystic carcinomachemotherapyimmunotherapymetastaticprostate

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Jonathan Q Trinh, Benjamin A Teply

Zitieren

APA

Trinh, J. Q., Lele, S. M., & Teply, B. A. (2023). A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease. The Prostate, 83(8), 814-819. https://doi.org/10.1002/pros.24521

Vancouver

Trinh JQ, Lele SM, Teply BA. A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease. The Prostate. 2023;83(8):814-819. doi:10.1002/pros.24521

BibTeX
@article{Trinh2023,
  author = {Trinh, Jonathan Q and Lele, Subodh M and Teply, Benjamin A},
  title = {A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease},
  journal = {The Prostate},
  year = {2023},
  volume = {83},
  number = {8},
  pages = {814--819},
  doi = {10.1002/pros.24521}
}
Kostenlos starten →